Acquisition Pending

Kuva Labs acquisition of Lisata Therapeutics

Announced 6 Mar 2026 · NASDAQ: LSTA · US$4.00 cash per share

Advisers

Lisata Therapeutics

Target

Financial adviser
Legal adviser
Fairness opinion

Kuva Labs

Acquirer

Legal adviser
Shackelford, McKinley & Norton, LLP
Information Agent for the Offer
Target
Lisata Therapeutics
Acquirer
Kuva Labs
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Oncology, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.